Found: 12
Select item for more details and to access through your institution.
A phase I trial of lurbinectedin in combination with cisplatin in patients with advanced solid tumors.
- Published in:
- Investigational New Drugs, 2022, v. 40, n. 1, p. 91, doi. 10.1007/s10637-021-01142-1
- By:
- Publication type:
- Article
First-in-human phase I study of the microtubule inhibitor plocabulin in patients with advanced solid tumors.
- Published in:
- Investigational New Drugs, 2019, v. 37, n. 4, p. 674, doi. 10.1007/s10637-018-0674-x
- By:
- Publication type:
- Article
Quantitative determination of lurbinectedin, its unbound fraction and its metabolites in human plasma utilizing ultra-performance LC–MS/MS.
- Published in:
- PLoS ONE, 2023, v. 17, n. 3, p. 1, doi. 10.1371/journal.pone.0283783
- By:
- Publication type:
- Article
A model-based head-to-head comparison of single-agent lurbinectedin in the pivotal ATLANTIS Study.
- Published in:
- Frontiers in Oncology, 2023, p. 1, doi. 10.3389/fonc.2023.1152371
- By:
- Publication type:
- Article
Population Pharmacokinetic‐Pharmacodynamic Modeling and Covariate Analyses of Neutropenia and Thrombocytopenia in Patients With Solid Tumors Treated With Lurbinectedin.
- Published in:
- Journal of Clinical Pharmacology, 2021, v. 61, n. 9, p. 1206, doi. 10.1002/jcph.1886
- By:
- Publication type:
- Article
Phase I study of plitidepsin in combination with bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma.
- Published in:
- Cancer Medicine, 2023, v. 12, n. 4, p. 3999, doi. 10.1002/cam4.5250
- By:
- Publication type:
- Article
Population-Pharmacokinetic and Covariate Analysis of Lurbinectedin (PM01183), a New RNA Polymerase II Inhibitor, in Pooled Phase I/II Trials in Patients with Cancer.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Anti-cancer drug combinations approved by US FDA from 2011 to 2021: main design features of clinical trials and role of pharmacokinetics.
- Published in:
- 2022
- By:
- Publication type:
- journal article
Integrated exposure–response analysis of efficacy and safety of lurbinectedin to support the dose regimen in small-cell lung cancer.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2022, v. 89, n. 5, p. 585, doi. 10.1007/s00280-021-04366-3
- By:
- Publication type:
- Article
Effect of lurbinectedin on the QTc interval in patients with advanced solid tumors: an exposure-response analysis.
- Published in:
- 2021
- By:
- Publication type:
- journal article
Impact of a Moderate CYP3A4 Inducer (Bosentan) on Lurbinectedin Pharmacokinetics and Safety in Patients with Advanced Solid Tumors: An Open-Label, Two-Way, Crossover, Phase Ib Drug–Drug Interaction Study.
- Published in:
- Pharmaceuticals (14248247), 2024, v. 17, n. 2, p. 182, doi. 10.3390/ph17020182
- By:
- Publication type:
- Article
Pharmacokinetics and Safety of Lurbinectedin Administrated with Itraconazole in Cancer Patients: A Drug–Drug Interaction Study.
- Published in:
- Marine Drugs, 2024, v. 22, n. 4, p. 178, doi. 10.3390/md22040178
- By:
- Publication type:
- Article